JP7748288B2 - リーダー配列 - Google Patents

リーダー配列

Info

Publication number
JP7748288B2
JP7748288B2 JP2021572387A JP2021572387A JP7748288B2 JP 7748288 B2 JP7748288 B2 JP 7748288B2 JP 2021572387 A JP2021572387 A JP 2021572387A JP 2021572387 A JP2021572387 A JP 2021572387A JP 7748288 B2 JP7748288 B2 JP 7748288B2
Authority
JP
Japan
Prior art keywords
pvc
seq
effector
payload
needle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021572387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535283A (ja
Inventor
アール. ウォーターフィールド,ニコラス
ヒーリー,ジョセフ
ハペシー,アレクシア
Original Assignee
ナノシュリンクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナノシュリンクス リミテッド filed Critical ナノシュリンクス リミテッド
Publication of JP2022535283A publication Critical patent/JP2022535283A/ja
Priority to JP2025064761A priority Critical patent/JP7866663B2/ja
Application granted granted Critical
Publication of JP7748288B2 publication Critical patent/JP7748288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2021572387A 2019-06-07 2020-06-05 リーダー配列 Active JP7748288B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064761A JP7866663B2 (ja) 2019-06-07 2025-04-10 リーダー配列

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
GB1908155.3 2019-06-07
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064761A Division JP7866663B2 (ja) 2019-06-07 2025-04-10 リーダー配列

Publications (2)

Publication Number Publication Date
JP2022535283A JP2022535283A (ja) 2022-08-05
JP7748288B2 true JP7748288B2 (ja) 2025-10-02

Family

ID=67386182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572387A Active JP7748288B2 (ja) 2019-06-07 2020-06-05 リーダー配列
JP2025064761A Active JP7866663B2 (ja) 2019-06-07 2025-04-10 リーダー配列

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064761A Active JP7866663B2 (ja) 2019-06-07 2025-04-10 リーダー配列

Country Status (12)

Country Link
US (1) US20230076614A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980545A1 (cg-RX-API-DMAC7.html)
JP (2) JP7748288B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220133757A (cg-RX-API-DMAC7.html)
CN (1) CN114008205A (cg-RX-API-DMAC7.html)
AU (1) AU2020288380B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024592A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142462A1 (cg-RX-API-DMAC7.html)
GB (1) GB201908155D0 (cg-RX-API-DMAC7.html)
MX (1) MX2021015121A (cg-RX-API-DMAC7.html)
SG (1) SG11202113297RA (cg-RX-API-DMAC7.html)
WO (1) WO2020245611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554283A (zh) * 2022-01-29 2023-08-08 中国医学科学院病原生物学研究所 多肽注射系统及其用途
EP4479082A4 (en) 2022-02-15 2026-06-10 Broad Inst Inc CELL-TYPE SPECIFIC TARGETING CONTRACTILE INJECTION SYSTEM
EP4547848A1 (en) 2022-06-30 2025-05-07 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用
GB202417349D0 (en) 2024-11-26 2025-01-08 Nanosyrinx Ltd Method of purification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US9951340B2 (en) * 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
RU2755282C2 (ru) * 2015-10-14 2021-09-14 Байер Кропсайенс Лп Ген ахм1554, кодирующий дельта-эндотоксин, и способы его применения

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUCHAUD. E. et al.,Nature Biotechnology,2003年,Vol.21, No.11,pp.1307-1313
JUBELIN, G. et al.,PLOS ONE,2009年,Vol.4, No.3, e4855,pp.1-13
VISIDOU, I. et al.,Photorhabdus Virulence Cassettes: extracellular multi-protein needle complexes for delivery of small protein effectors into host cells,bioRxiv preprint,2019年02月15日,doi.org/10.1101/549964

Also Published As

Publication number Publication date
CA3142462A1 (en) 2020-12-10
SG11202113297RA (en) 2021-12-30
JP7866663B2 (ja) 2026-05-27
AU2020288380B2 (en) 2026-07-09
BR112021024592A2 (pt) 2022-01-18
US20230076614A1 (en) 2023-03-09
EP3980545A1 (en) 2022-04-13
WO2020245611A1 (en) 2020-12-10
MX2021015121A (es) 2022-03-17
KR20220133757A (ko) 2022-10-05
CN114008205A (zh) 2022-02-01
JP2025114573A (ja) 2025-08-05
GB201908155D0 (en) 2019-07-24
JP2022535283A (ja) 2022-08-05
AU2020288380A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
JP2025114573A (ja) リーダー配列
Kim et al. Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa
Garcia et al. Antimicrobial peptides from arachnid venoms and their microbicidal activity in the presence of commercial antibiotics
Bartels et al. Dermaseptins, multifunctional antimicrobial peptides: A review of their pharmacology, effectivity, mechanism of action, and possible future directions
Graf et al. Proline-rich antimicrobial peptides targeting protein synthesis
Cianfanelli et al. VgrG and PAAR proteins define distinct versions of a functional type VI secretion system
Edwards et al. Contribution of amphipathicity and hydrophobicity to the antimicrobial activity and cytotoxicity of β-hairpin peptides
Zhao et al. Nisin-and ripcin-derived hybrid lanthipeptides display selective antimicrobial activity against Staphylococcus aureus
Corrales-Garcia et al. Bacterial expression and antibiotic activities of recombinant variants of human β-defensins on pathogenic bacteria and M. tuberculosis
Bagheri et al. Mode of action of cationic antimicrobial peptides defines the tethering position and the efficacy of biocidal surfaces
US10131888B2 (en) Intracellular protein delivery
Libardo et al. Copper-binding tripeptide motif increases potency of the antimicrobial peptide Anoplin via Reactive Oxygen Species generation
Koo et al. Functional mapping of PilF and PilQ in the Pseudomonas aeruginosa type IV pilus system
González-Magaña et al. The P. aeruginosa effector Tse5 forms membrane pores disrupting the membrane potential of intoxicated bacteria
BRPI0620125A2 (pt) método para regulação de redução da função biológica de uma proteìna, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra
Salazar et al. Exploring the mechanisms of action of human secretory RN ase 3 and RN ase 7 against Candida albicans
US20240254169A1 (en) Protein and peptide delivery systems and methods for making and using them
Li et al. Antibacterial activity and mechanism of the cell-penetrating peptide CF-14 on the gram-negative bacteria, Escherichia coli
CN107022001A (zh) 一种分离的母乳内源性抗菌多肽及其应用
Ajish et al. Proadrenomedullin N-terminal 20 peptide (PAMP) and its C-terminal 12-residue peptide, PAMP (9–20): Cell selectivity and antimicrobial mechanism
EP3663311A1 (en) Chimeric protein switch for the optogenetic control of amyloidogenesis
Alaybeyoglu et al. The effect of a beta‐lactamase inhibitor peptide on bacterial membrane structure and integrity: a comparative study
Cermenati et al. The CPP Tat enhances eGFP cell internalization and transepithelial transport by the larval midgut of Bombyx mori (Lepidoptera, Bombycidae)
KR20210066752A (ko) 신규한 세포막 투과성 단백질 및 이의 용도
KR101810630B1 (ko) 항균, 항진균 및 항암 활성을 갖는 펩타이드 및 이의 용도

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230411

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20231011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250919

R150 Certificate of patent or registration of utility model

Ref document number: 7748288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150